This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For the nation’s largest health insurer, the evidence of abuse was stunning and unmistakable: UnitedHealth Group reaped billions from the federal Medicare program by diagnosing patients with serious chronic illnesses, and then delivering no follow-up care. The findings in the federal report reveal that UnitedHealth repeatedly sent clinicians into patients’ homes and pored over their medical charts to add diagnoses for illnesses such as vascular disease, heart failure, and diabetes.
For people with obesity, surgeries that shrink, reshape, or otherwise alter the anatomy of the stomach have long reigned supreme as the surest way to weight loss. But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound , more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a population level, among a subset of commercially insured individuals, that is the tradeoff that is happening” said Thomas Tsai, th
Single-use disposable vapes will be banned in England and Wales from summer next year, the government has confirmed. New legislation to prohibit the sales of single-use vapes will come into force on 1 June 2025, ministers said. Subject to parliamentary approval, businesses will have until then to sell any remaining stock and prepare for the […] The post Single-use vapes to be banned from next summer appeared first on The Pharmacist.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
When Chelsea Smith met Jason Martin she knew right away that he was the one — so she refused to get his phone number. That’s because getting married would make Smith ineligible for Social Security benefits and Medicaid — financial support that she and many others with disabilities need to survive. Smith didn’t want to risk falling in love knowing she couldn’t get married.
Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.
A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.
A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.
Michael Anne Kyle had just begun her Ph.D. in health policy and management at Harvard Business School when her friends started complaining about the health care system. Many of them were having children for the first time, and they’d never been to the doctor so much in their lives. They’d text Kyle, who is also an ICU nurse, with gripes.
A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Dr Reddy’s Laboratories has been recognised among the top employers in the global biotech and pharma sectors, according to the 2024 Top Biotech and Pharma Employers Survey by Science magazine. This marks the third consecutive year that Dr Reddy’s has secured a place in the survey’s top rankings. Dr Reddy’s first entered the list in 2022, ranked 18th.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Fun fact: My Ph.D. dissertation was about destroying toxic “forever chemicals,” aka PFAS. This mostly means I am cursed with knowing too much about where these chemicals are used.
The 2024 Top Biotech and Pharma Employers Survey conducted by Science magazine has revealed the top 20 employers in the global biotech and pharmaceutical sectors. The survey gathered insights from employees working in biotechnology, biopharmaceutical, pharmaceutical, and related industries, highlighting the companies that stand out as preferred workplaces.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to manicure the Pharmalot grounds, promenade with the official mascots, and sample some natural wonders. We also hope to hold another listening party, where the rotation will likely include this , this , this , this , and this.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
The government does not hold information on how many and what proportion of community pharmacies have dispensed medications at a loss, the minister of state for care has said. But the National Pharmacy Association (NPA) has estimated this number at 85% of its independent contractor members and warned that 'frequently, pharmacies find themselves losing out'. […] The post Pharmacies ‘losing out’ while government unsure how many dispense at a loss appeared first on The Pharmacist.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
New clinical data has shown a potential best-in-class next-generation antibody-drug conjugate (ADC) can offer promising response rates in extensive-stage small cell lung cancer. The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. Overall response rate was 74 percent in individuals with at least one post-treatment evaluation.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Explore the potential of AI in navigating the vast amounts of data in clinical trials. Discover how this technology is revolutionising the healthcare industry, in a new Tech & Trials column.
The medicines regulator has urged pharmacists to be alert to signs of ‘misuse’ of GLP-1 receptor agonists for weight loss, such as semaglutide. Healthcare professionals should also ensure patients are aware of the side-effects of the diabetes and weight loss injections and report any adverse reactions through the Yellow Card reporting scheme, the Medicines and Healthcare […] The post MHRA urges pharmacists to be alert to signs of GLP-1 RA ‘misuse’ appeared first on The Pharmacist.
NICE backs two AI algorithms from Boston Scientific and Medtronic for monitoring heart failure patients, but turns down others from Biotronik and Abbott.
SOBI and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The VALIANT trial is a double-blind, randomised, multi-centre and placebo-controlled study that aimed to evaluate the efficacy and safety of pegcetacoplan in 124 […] The post VALIANT phase 3 trial results highlight potential
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a longstanding partnership and Marinus said it would lay off staff.
Pacira Biosciences, spcecialist in non-opioid pain therapies, has appointed Shawn Cross as their chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations. “I am proud to join Pacira as I am strongly aligned with the company’s important mission to deliver innovative, non-opioid pain therapies.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service offering that harnesses Uniphar’s 55 years in the industry delivering specialist services to more than 200 international clients across 180 countries. Combining Uniphar’s established expertise and tailored strategies, the platform is designed to support pharmaceutical and biotech companies navigate the […] The post From molecule to market and beyond: Uniphar announces extended global c
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
363 
Let's personalize your content